Medical/Pharmaceuticals
Antengene Announces HREC Approval in Australia for the Phase I Trial of ATG-022 (Claudin 18.2 ADC) in Patients with Advanced or Metastatic Solid Tumors
* Discovered in-house by Antengene's R&D team, ATG-022 is an antibody-drug-conjugate targeting the Tumor Associated Antigen (TAA) Claudin 18.2 * The Phase I trial is designed to evaluate the safety, pharmacology, and preliminary efficacy of ATG-022 as a monotherapy in patients withadvanced or...
2022-12-09 08:30
4025
Innovent Presents Phase Ib Clinical Data of IBI939 (Anti-TIGIT Monoclonal Antibody) in Previously Untreated PD-L1-selected NSCLC at the 2022 European Society For Medical Oncology Immuno-Oncology Congress
ROCKVILLE, Md. and SUZHOU, China, Dec 9, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and ...
2022-12-09 08:00
4651
Innovent Presents Phase Ib Clinical Data Update of IBI110 (Anti-LAG-3 Monoclonal Antibody) at the 2022 European Society For Medical Oncology Immuno-Oncology Congress
ROCKVILLE, Md. and SUZHOU, China, Dec. 9, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and...
2022-12-09 08:00
4796
SK Biopharmaceuticals' Partner Angelini Pharma Launches Cenobamate in France
Cenobamate (ONTOZRY®), for the treatment of uncontrolled focal-onset seizures in adults, is now available in 5 major European countries –Germany, the UK, Italy, Spain, France – and 10 other key markets PANGYO, South Korea, Dec. 8, 2022 /PRNewswire/ -- SK Biopharmaceuticals, an innovative global ...
2022-12-09 06:30
3330
ReviR Therapeutics to Present at RNA Targeted Drug Discovery Summit
SAN FRANCISCO, Calif., Dec. 8, 2022 /PRNewswire/ -- ReviR Therapeutics (ReviR), a biotechnology company developing small molecule therapies targeting RNA, today announced an upcoming presentation at the 5th Annual RNA Targeted Drug Discovery conference taking placeDecember 13-15, 2022 in Boston, ...
2022-12-08 23:00
3475
LISCure's Phase 2 Drug Candidate Granted Orphan Drug Designation (ODD) from US FDA
First Orphan Drug Designation (ODD) in the field of microbiome-based treatment for metabolic diseases SEOUL, South Korea, Dec. 8, 2022 /PRNewswire/ -- LB-P8, a novel drug being developed by LISCure Biosciences, Inc. (LISCure) as a treatment for Primary Sclerosing Cholangitis (PSC), has been desi...
2022-12-08 22:00
2878
TrialWire Awarded by Frost & Sullivan for Innovative Clinical Trial Patient Recruitment Technology Platform
TrialWire delivers superior trial patient recruitment solutions based on highly sophisticated information technology (IT) all in one secure platform SAN ANTONIO, Dec. 8, 2022 /PRNewswire/ -- Based on its recent analysis of the clinical trial patient recruitment IT solutions industry,Frost & Sulli...
2022-12-08 22:00
3910
PharmAbcine to Participate in the 41th Annual J.P. Morgan Healthcare Conference and Biotech Showcase™ 2023 during JPM Week
DAEJEON, South Korea, Dec. 8, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today that the Company is invited to participate in upcoming 41th Annual J.P. Morgan Healthcare ...
2022-12-08 21:00
2748
SonarMed™ airway monitoring system Applauded by Frost & Sullivan for Providing Real-time Visualization for Accurate Troubleshooting with Its Endotracheal Tube Airway Monitor
The SonarMed™ system is the first and only FDA-cleared airway monitoring system that provides heightened patient safety, cost savings, and quality measures while lowering average LOS in the NICU. SAN ANTONIO, Dec. 8, 2022 /PRNewswire/ -- Frost & Sullivan recently assessed the neonatal care indus...
2022-12-08 21:00
2692
Createrna Announces Positive Top-Line Results from Phase 1 Clinical Trials of QR052107B Tablet in Healthy Volunteers
* QR052107B Tablet was safe and well tolerated in healthy volunteers across all tested doses, with no taste related adverse event at the anticipated therapeutic doses * Createrna initiated a clinical Phase 2 trial to study QR052107B Tablet at once-a-day (QD) dose in the treatment of refract...
2022-12-08 14:29
2893
Antengene Appoints Amily Zhang as its Chief Medical Officer
SHANGHAI and HONG KONG, Dec. 8, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hema...
2022-12-08 08:30
4579
HARRISON.AI NAMED ON THE 2022 CB INSIGHTS' DIGITAL HEALTH 150 LIST
The clinician-led technology platform has been recognized for achievements in
computer-aided imaging
NEW YORK, Dec. 8, 2022 /PRNewswire/ -- CB Insights
2022-12-08 06:00
3207
BSR KOREA Introduces "Wizbiosolutions Inc." as "2022 Global Procurement Marketer"
SEOUL, South Korea, Dec. 7, 2022 /PRNewswire/ -- As the practitioner of "2022 Global Procurement Marketer (GPM) Project" promoted by the Ministry of SMEs and Startups (MSS) and Korea SMEs and Startups Agency (KOSME), BSR KOREA offered consultation for 40 domestic SMEs that want to enter the inter...
2022-12-08 00:00
3295
Ascletis Announces IND Approval of Oral 3CLpro Inhibitor ASC11 for COVID-19 by China NMPA
--The objective of Phase I clinical trial is to identify a safe and efficacious dose for the pivotal Phase II/III in COVID-19 patients. Phase I clinical trial is expected to be completed within the first quarter of 2023 --Phase I clinical trial will also determine if ASC11 needs to be boosted by ...
2022-12-07 18:10
4892
Pharming announces publication of data from Phase 3 Study of leniolisib in patients with APDS in ASH's Blood
Leniolisib was well tolerated and significant improvement over placebo was notable in the co-primary endpoints, reflecting a favorable impact on patients' immune dysregulation and deficiency The peer-reviewed publication heightens international understanding of APDS, a rare and recently characte...
2022-12-07 14:00
4533
Apollo Proton Cancer Centre successfully performs Asia's 1st Brain Bypass Surgery on twin children with Moya Moya Disease
CHENNAI, India, Dec. 7, 2022 /PRNewswire/ -- Apollo Proton Cancer Centre (APCC) recently performedAsia's first brain bypass surgery on twin 8-year-old children fromthe Netherlands. The integration of advanced technology and expertise at APCC helped the children to undergo surgery and recover quic...
2022-12-07 13:17
4008
PGTG successfully develops SGF bone-derived factor to restore the skeletal system
BEIJING, Dec. 7, 2022 /PRNewswire/ -- The bone-derived skeletal growth factor (SGF), jointly developed by a research facility under the direction of leading biochemist, academician and researcher Zhao Yufen and theAnhui-based research center of one of the world's health industry leaders People's ...
2022-12-07 12:00
2610
SmartFuture launches SDK to enable plug-and-play Remote Patient Monitoring in existing healthcare payer and provider applications
SINGAPORE, Dec. 7, 2022 /PRNewswire/ -- SmartFuture, a leading health-tech company and provider of integrated RPM (Remote Patient Monitoring) solutions, has launched anRPM SDK (Software Development Kit) product. SmartFuture's RPM SDK product allows healthcare providers and payers to integrate wh...
2022-12-07 10:36
3617
Suvoda Launches eCOA-Specific Language and Design Toolkit as Solution Moves to Second Phase of Early Adopter Program
Practical, innovative functionality seeks to alleviate eCOA burdens, reduce time-to-launch, and improve site, clinician, and patient experience. PHILADELPHIA, Dec. 7, 2022 /PRNewswire/ -- Suvoda LLC, a global clinical trial technology company that specializes in complex studies in therapeutic ar...
2022-12-07 08:00
3081
Veeva Pulse Shows Digitally Enabled Field Teams are Using HCP Time More Effectively in Asia Pacific
HCP Access is selective as nearly half meet with only one company monthly
SINGAPORE, Dec. 7, 2022 /PRNewswire/ -- Veeva Systems
2022-12-07 08:00
4624
Week's Top Stories
Most Reposted
Cyient, 3-GIS Partner to Help Telecom and Utility Operators Turn Network Data into Operational Control
[Picked up by 1154 media titles]
2026-11-11 22:00Royal Bank of Canada announces agreement to acquire Yarra Capital Management
[Picked up by 1143 media titles]
2026-11-09 21:00Algolia Powers Orange with AI Agents for Billing Support: NYSE Content Update
[Picked up by 1121 media titles]
2026-11-06 22:06
Cision Report Reveals the Consumer Trends Hidden Between Search, Social, and AI
[Picked up by 1109 media titles]
2026-11-09 23:00
Poppi Founders Launch Hydration Brand jetty: NYSE Content Update
[Picked up by 1083 media titles]
2026-11-10 22:17
Most Read
Home Companion Robot Mobo to Debut Globally and Open Pre-orders as AiMOGA Showcases Its Robot Family at the 2026 OMODA & JAECOO International User Summit
2026-11-07 13:49
26800
ZD Energy Unveils Overseas Smart Energy Solutions in Thailand, Leveraging Local Manufacturing and Scenario-Based Capabilities to Support the Country's Energy Transition
2026-11-06 22:12
15724
SILVERSEA MARKS HISTORIC OPENING OF THE CORMORANT AT 55 SOUTH, THE SOUTHERNMOST HOTEL ON EARTH, OFFERING A NEW GATEWAY TO ANTARCTICA
2026-11-07 01:05
15189
Algolia Powers Orange with AI Agents for Billing Support: NYSE Content Update
2026-11-06 22:06
12267